Clinical Trials Logo
  1. Home
  2. Circulating Tumor Cells
  3. NCT02499458

Prospective Validation of Circulating Tumor Cells & Circulating Endothelial Cells as Biomarkers in Renal Cancer

Circulating Tumor Cells Clinical Trial

Official title:
Prospective Validation of Circulating Tumor Cells (CTCs) and Circulating Endothelial Cells (CECs) as Prognostic Biomarkers in Clear Cell Renal Cancer

Clinical Trial Summary

Circulating tumor cells (CTCs) have prognostic value in several tumor types, and increasing evidence suggests that molecular characterization of CTCs can serve as a "liquid biopsy" to understand and address treatment resistance. The goal of this proposal is to demonstrate that CTCs can be accurately enumerated and characterized in metastatic clear cell renal cancer (CCRC) and can serve as prognostic/predictive biomarkers to improve treatment. The challenge surrounding CTC analysis in CCRC is that most CTC technologies (including the clinical gold-standard CellSearch®) depend in epithelial markers such as EpCAM that are expressed at low or heterogeneous levels in CCRC. Members of the research team have developed a novel CTC microfluidic technology that can effectively detect CTCs that are completely undetectable by CellSearch® because of very low EpCAM expression, as well as allowing for CTC recovery for downstream molecular characterization. The goal of this proposal is therefore to test the hypotheses that (1) The microfluidics CTC technology will have better sensitivity/specificity relative to the CellSearch in metastatic CCRC; and (2) Enumeration of CTCs in metastatic CCRC patients (n=66) will have prognostic value, while molecular characterization of CTCs for expression of biomarkers (VHL, VEGF, mTOR, HIF1/HIF2, AKT) related to CCRC etiology will be predictive of response/resistance to targeted therapies. Although CCRC is relatively uncommon, the lack of established adjuvant treatments and high cost of targeted therapies in the palliative setting makes the search for new prognostic/predictive biomarkers an important clinical goal.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02499458
Study type Observational
Source Lawson Health Research Institute
Contact
Status Completed
Phase
Start date November 2014
Completion date December 2018
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT02072616 - Detection of Circulating Tumor Cells for the Diagnostic of Pancreatic Adenocarcinoma. Phase 3
Completed NCT02808884 - Cancer DNA Screening Pilot Study (CANDACE) N/A
Recruiting NCT06068348 - Liquid Biopsy Collection Study
Completed NCT02335151 - CTC Pancreatic Adenocarcinoma Phase 4
Completed NCT01015625 - Primary Operation in SYnchronous meTastasized InVasivE Breast Cancer N/A
Recruiting NCT02602938 - Aspirin on CTCs of Advanced Breast and Colorectal Cancer Phase 2
Completed NCT03101046 - Treatment of Metastatic Castrate Resistant Prostate Cancer Patients According to Circulating Tumor Cells Kinetic Phase 2
Completed NCT02449837 - Investigation of Circulating Tumor Cells From Cancer Patients Undergoing Radiation Therapy
Recruiting NCT02451384 - According CTC to Compare the Influences of Different Methods to Remove the PDAC N/A
Recruiting NCT01052818 - Therapeutic and Prognostic Impact of Circulating Tumor Cells in Peripheral Blood in Patients With Non Small-cell Lung Cancer N/A
Not yet recruiting NCT04239105 - Detection of Circulating Tumor Cells in Breast Cancer Patients Using a Novel Microfluidic and Raman Spectrum Device
Recruiting NCT03156777 - Application Value of CTCs Detection for Advanced Gastric Cancer Patients N/A
Recruiting NCT02554448 - Detection of CTCs in Stage III Rectal Cancer Patients Undergoing Neoadjuvant Therapy N/A
Completed NCT02345473 - Detection and Clinical Significance of Circulating Cancer Cells in Patient Undergoing Radical Cystectomy N/A
Not yet recruiting NCT04229121 - Clinical Sensitivity Verification Study of Circulating Tumor Cells Gene Mutation Detection From Advanced NSCLC Patients
Completed NCT02955173 - Significance of Circulating Tumor Cells in the Treatment of Gastric and Rectal Cancer N/A
Completed NCT03340844 - Role of CTC´s Spread During Pancreaticoduodenectomy in Patients With Pancreatic and Periampullary Tumors N/A
Active, not recruiting NCT03381326 - CTC, Free DNA, Stem Cells and EMT-related Antigens as Biomarkers of Activity of Cabazitaxel in CRPC.
Completed NCT05502458 - Effect of Propofol and Desflurane on Nucleic Acid of Liver Circulating Tumor Phase 2
Enrolling by invitation NCT04972461 - Therapeutic Response Evaluation by CTC Expansion System